Cao H, Song X K, Hong Y G
Department of Medical Oncology, Anyang Tumor Hospital, the Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang 455000, China.
Information Technologic College, Henan University of Chinese Medicine, Zhengzhou 450000, China.
Zhonghua Zhong Liu Za Zhi. 2021 Aug 23;43(8):856-860. doi: 10.3760/cma.j.cn112152-20200104-00005.
To evaluate the expression of semaphorin 5B (SEMA5B) in gastric adenocarcinoma and its relationship with prognosis. In November 2019, the clinicopathological characteristics and SEMA5B mRNA expression data of 341 patients with gastric adenocarcinoma were collected through TCGA database. The relationship between SEMA5B expression in gastric adenocarcinoma tissues and clinical pathologic features and overall survival were analyzed. Gene Set Enrichment Analysis (GSEA) was used to analyze the signaling pathways regulated by SEMA5B. The expression level of SEMA5B mRNA in 341 gastric adenocarcinoma tissues was 0.577±0.587, in adjacent normal tissues was 0.132±0.075, the difference was statistically significant (<0.001). The median survival time of 109 patients with high expression of SEMA5B mRNA was 14.5 months, 232 patients with low expression of SEMA5B mRNA was 17.9 months (=0.047). Univariate analysis showed that the expression of SEMA5B mRNA was correlated with histological grade and T stage (<0.05). The multivariate analysis revealed that age<65 years remained independently associated with overall survival, with a hazard ratio() of 1.042 (95% 1.021-1.064). The multivariate analysis revealed that high expression of SEMA5b mRNA remained independently associated with overall survival, with a of 1.195 (95% 0.925-2.551). GSEA showed that malignant tumor signaling pathways (=0.008), MAPK signaling pathways (=0.047) and Notch signaling pathways (=0.029) were differentially enriched in SEMA5B highly expressed phenotype. SEMA5B expression may be a potential prognostic molecular marker for prognosis of GAC patients. Moreover, malignant tumor signaling pathway, MAPK signaling pathway and Notch signaling pathway may be the key pathway regulated by SEMA5B in GAC.
评估信号素5B（SEMA5B）在胃腺癌中的表达及其与预后的关系。2019年11月，通过TCGA数据库收集了341例胃腺癌患者的临床病理特征和SEMA5B mRNA表达数据。分析胃腺癌组织中SEMA5B表达与临床病理特征及总生存期的关系。采用基因集富集分析（GSEA）分析SEMA5B调控的信号通路。341例胃腺癌组织中SEMA5B mRNA表达水平为0.577±0.587，癌旁正常组织为0.132±0.075，差异有统计学意义（<0.001）。109例SEMA5B mRNA高表达患者的中位生存时间为14.5个月，232例SEMA5B mRNA低表达患者为17.9个月（P=0.047）。单因素分析显示，SEMA5B mRNA表达与组织学分级和T分期相关（<0.05）。多因素分析显示，年龄<65岁仍与总生存期独立相关，风险比（HR）为1.042（95%可信区间1.021-1.064）。多因素分析显示，SEMA5B mRNA高表达仍与总生存期独立相关，HR为1.195（95%可信区间0.925-2.551）。GSEA显示，恶性肿瘤信号通路（P=0.008）、MAPK信号通路（P=0.047）和Notch信号通路（P=0.029）在SEMA5B高表达表型中差异富集。SEMA5B表达可能是胃腺癌患者预后的潜在预后分子标志物。此外，恶性肿瘤信号通路、MAPK信号通路和Notch信号通路可能是SEMA5B在胃腺癌中调控的关键通路。
